Glial fibrillary acidic protein is a robust biomarker in cerebrospinal fluid and peripheral blood after traumatic spinal cord injury: a prospective pilot study.

Autor: Wichmann TO; Dept. of Neurosurgery, Cense-Spine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200, Aarhus N, Denmark. Thewic@rm.dk., Kasch H; Dept. of Neurology, Aarhus University Hospital, Aarhus, Denmark.; Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark., Dyrskog S; Dept. of Intensive Care, Aarhus University Hospital, Aarhus, Denmark., Høy K; Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Dept. of Orthopaedic Surgery-Spine section, Aarhus University Hospital, Aarhus, Denmark., Møller BK; Dept. of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark., Krog J; Dept. of Anaesthesiology, Aarhus University Hospital, Aarhus, Denmark., Hoffmann HJ; Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Dept. of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark., Hviid CVB; Dept. of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.; Dept. of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark., Rasmussen MM; Dept. of Neurosurgery, Cense-Spine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200, Aarhus N, Denmark.; Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jazyk: angličtina
Zdroj: Acta neurochirurgica [Acta Neurochir (Wien)] 2023 Jun; Vol. 165 (6), pp. 1417-1425. Date of Electronic Publication: 2023 Feb 15.
DOI: 10.1007/s00701-023-05520-x
Abstrakt: Purpose: Biochemical biomarkers to determine the injury severity and the potential for functional recovery of traumatic spinal cord injury (TSCI) are highly warranted; however, it remains to be clarified whether cerebrospinal fluid (CSF) or peripheral blood (PB) is the ideal sample media. This study aims to measure and compare biomarker concentrations in CSF and PB and to explore associations between biomarker concentrations and injury severity, i.e., American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade, and biomarker concentrations and clinical outcome, i.e., AIS grade improvement and Spinal Cord Independent Measure version III (SCIM-III) score.
Methods: From 2018 to 2020, we conducted a single-center prospective pilot study of TSCI patients (n=15) and healthy controls (n=15). Sample collection and clinical outcome assessment were performed at median 13 h [IQR: 19], 9 days [IQR: 2], and 148 days [IQR: 49] after TSCI. Concentrations of neuron-specific enolase (NSE); glial fibrillary acid protein (GFAP); neurofilament light chain (NfL); interferon-γ (IFN-γ); interleukin (IL)-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13; and tumor necrosis factor α (TNF-α) were measured and associated to clinical outcomes.
Results: The biomarker concentrations were higher in CSF than PB. CSF concentrations of GFAP, NSE, IFN-y, TNF-a, IL-2, IL-12p70, IL-4, IL-10, and IL-13 and PB concentrations of GFAP and IFN-y were significantly associated with AIS grade, but not with AIS grade improvement or SCIM-III score.
Conclusions: Our results support GFAP as a potential diagnostic biomarker that may be measured in CSF as well as PB.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: